TScan Therapeutics/$TCRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Ticker
$TCRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
201
ISIN
US89854M1018
Website
TCRX Metrics
BasicAdvanced
$84M
-
-$2.32
0.97
-
Price and volume
Market cap
$84M
Beta
0.97
52-week high
$7.89
52-week low
$1.02
Average daily volume
697K
Financial strength
Current ratio
8.547
Quick ratio
8.441
Long term debt to equity
43.799
Total debt to equity
46.164
Interest coverage (TTM)
-41.42%
Profitability
EBITDA (TTM)
-136.166
Gross margin (TTM)
-121.15%
Net profit margin (TTM)
-2,974.08%
Operating margin (TTM)
-3,159.87%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-30.45%
Return on equity (TTM)
-78.93%
Valuation
Price to revenue (TTM)
18.945
Price to book
0.4
Price to tangible book (TTM)
0.4
Price to free cash flow (TTM)
-0.677
Free cash flow yield (TTM)
-147.81%
Free cash flow per share (TTM)
-218.75%
Growth
Revenue change (TTM)
-70.15%
Earnings per share change (TTM)
14.99%
3-year revenue growth (CAGR)
-26.50%
3-year earnings per share growth (CAGR)
-10.83%
What the Analysts think about TCRX
Analyst ratings (Buy, Hold, Sell) for TScan Therapeutics stock.
TCRX Financial Performance
Revenues and expenses
TCRX Earnings Performance
Company profitability
TCRX News
AllArticlesVideos
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
GlobeNewsWire·4 weeks ago
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewsWire·2 months ago
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TScan Therapeutics stock?
TScan Therapeutics (TCRX) has a market cap of $84M as of June 27, 2025.
What is the P/E ratio for TScan Therapeutics stock?
The price to earnings (P/E) ratio for TScan Therapeutics (TCRX) stock is 0 as of June 27, 2025.
Does TScan Therapeutics stock pay dividends?
No, TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next TScan Therapeutics dividend payment date?
TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for TScan Therapeutics?
TScan Therapeutics (TCRX) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.